Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells. Dr. Shankar has already successfully used RNAi to dramatically suppress HIV infection in mice by knocking down three key genes which prevented the HIV infection from spreading.
Bioo Scientific’s T3 Technology will allow Dr Shankar to precisely target the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA or miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the monoclonal antibody. The RNAi agent is then released to reduce the expression of its intended target. T3 technology can propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
“I am delighted to join forces with Bioo Scientific in the development of an advanced monoclonal antibody based technology for targeted delivery of siRNA to T cells and potentially other cell types” Dr. Shankar said. “By combining our scientific expertise and resources, we can speed up the development of robust enabling platforms for efficient delivery to desired cells and tissues in vivo which is critical for translating siRNAs into a novel class of drugs to treat human diseases.”
About Bioo Therapeutics
Bioo Therapeutics is a division of Bioo Scientific, is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. For more information about Bioo Therapeutics, visit www.biootherapeutics.com.
Monday, November 16, 2009
Friday, November 13, 2009
Bioo Scientific Launches a New Division, Bioo Therapeutics
Bioo Therapeutics, a division of Bioo Scientific, was launched today to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. Bioo Therapeutics flagship drug delivery technology is a patent pending antibody conjugation technology which delivers small RNA drugs into specifically targeted cells or tissues. The scientists at Bioo Scientific have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target. Drugs or toxins can be attached to monoclonal antibodies which target a specific cell type forming monoclonal antibody conjugates. These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells. This patent pending technology can revolutionize the delivery of siRNA and other RNAi agents, as well as, other more traditional drugs.
"Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer," said Lance Ford, VP of Research and Business Development for Bioo Scientific. This research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.
About Bioo Therapeutics
Bioo Therapeutics is a division of Bioo Scientific, is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. For more information about Bioo Therapeutics, visit http://www.biootherapeutics.com.
"Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer," said Lance Ford, VP of Research and Business Development for Bioo Scientific. This research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.
About Bioo Therapeutics
Bioo Therapeutics is a division of Bioo Scientific, is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. For more information about Bioo Therapeutics, visit http://www.biootherapeutics.com.
Thursday, October 15, 2009
Bioo Scientific Won Tech Innovation Award for Technology that Detects Melamine Contamination
The Director of Protein Chemistry and Engineering at Bioo Scientific, Dr Joe Krebs, won the Austin Business Journal’s 2009 Tech Innovator of the Year award in the Biotech/Medical division, for his work on the MaxSignal® Melamine Enzymatic Assay Kit. Eighty six people who demonstrated excellence in innovative technological advancement were nominated for the 2009 Tech Innovator of the Year award. Dr Krebs won this award because his work on this kit will protect our food and pharmaceutical supply by allowing companies and government agencies to quickly and inexpensively screen for melamine contamination. The MaxSignal® Melamine Enzymatic Assay Kit is a low-cost, high-throughput colorimetric test kit, which detects melamine in food and pharmaceutical samples.
Recently, melamine has rapidly emerged as a major threat to the world’s food and pharmaceutical supplies. Melamine is a dangerous, nitrogen rich organic compound that is illegally added to food and feed to increase the apparent protein content values of food products. Consumption of melamine causes highly insoluble melamine cyanurate crystals to form in the kidney, which damage renal cells and can result in renal failure or death. The recent establishment of a 1µg/g (1 ppm) safety threshold for melamine in infant foods has led to an immediate need for sensitive melamine detection methods.
Based on Bioo Scientific’s patent-pending technology, Dr Joe Krebs and Ms. Jessica Brill, developed a test that meets the requirements of low-cost, speed and simplicity which are desperately needed by food and feed safety customers; a community comprised of government regulatory agencies such as USDA and FDA analysts, as well as academic labs, food processing plants and retailers.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
As a world leader in food safety testing, Bioo Scientific is dedicated to improving the safety of the world’s food and feed supply by developing accurate, affordable tools, which allow companies to readily screen for pathogens and contaminants. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 40 countries. For more information about Bioo Scientific, visit www.biooscientific.com.
Recently, melamine has rapidly emerged as a major threat to the world’s food and pharmaceutical supplies. Melamine is a dangerous, nitrogen rich organic compound that is illegally added to food and feed to increase the apparent protein content values of food products. Consumption of melamine causes highly insoluble melamine cyanurate crystals to form in the kidney, which damage renal cells and can result in renal failure or death. The recent establishment of a 1µg/g (1 ppm) safety threshold for melamine in infant foods has led to an immediate need for sensitive melamine detection methods.
Based on Bioo Scientific’s patent-pending technology, Dr Joe Krebs and Ms. Jessica Brill, developed a test that meets the requirements of low-cost, speed and simplicity which are desperately needed by food and feed safety customers; a community comprised of government regulatory agencies such as USDA and FDA analysts, as well as academic labs, food processing plants and retailers.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
As a world leader in food safety testing, Bioo Scientific is dedicated to improving the safety of the world’s food and feed supply by developing accurate, affordable tools, which allow companies to readily screen for pathogens and contaminants. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 40 countries. For more information about Bioo Scientific, visit www.biooscientific.com.
Thursday, October 1, 2009
Bioo Scientific Awarded USDA Grant for Development of Technology to Detect Food Contaminants
The safety of the public food supply is an important global public health issue. Last year over 300,000 people were hospitalized with food poisoning in the US alone. Because of recent food contamination incidents, Congress just passed a sweeping reform of the food-safety system that will require improved testing of domestically produced and imported food. This reform increases the need for sensitive, reliable and affordable assays to screen and protect our food supply.
As a demonstration of the commitment by the US government to food safety, Bioo Scientific was awarded a Small Business Innovation Research (SBIR) Phase II grant totaling $350,000 from the US Department of Agriculture (USDA) for the development of a new technology to detect the presence of contaminants in food and feed. Bioo Scientific is developing innovative enzymatic assays that are ideal for the detection of low molecular weight analytes, such as melamine, which are too small to be measured accurately using ELISA assays (a traditional assay used for food testing). These assays will be an effective new tool for developing improved procedures for comprehensive yet cost-effective screening of food samples for melamine and other contaminants to better ensure the safety of our food and feed supply.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
As a world leader in food safety testing, Bioo Scientific is dedicated to improving the safety of the world’s food and feed supply by developing accurate, affordable tools, which allow companies to readily screen for pathogens and contaminants. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 40 countries. For more information about Bioo Scientific, visit www.biooscientific.com.
As a demonstration of the commitment by the US government to food safety, Bioo Scientific was awarded a Small Business Innovation Research (SBIR) Phase II grant totaling $350,000 from the US Department of Agriculture (USDA) for the development of a new technology to detect the presence of contaminants in food and feed. Bioo Scientific is developing innovative enzymatic assays that are ideal for the detection of low molecular weight analytes, such as melamine, which are too small to be measured accurately using ELISA assays (a traditional assay used for food testing). These assays will be an effective new tool for developing improved procedures for comprehensive yet cost-effective screening of food samples for melamine and other contaminants to better ensure the safety of our food and feed supply.
About Bioo Scientific Corporation
Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and for organizations that perform food and feed safety analysis.
As a world leader in food safety testing, Bioo Scientific is dedicated to improving the safety of the world’s food and feed supply by developing accurate, affordable tools, which allow companies to readily screen for pathogens and contaminants. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 40 countries. For more information about Bioo Scientific, visit www.biooscientific.com.
Thursday, August 27, 2009
Bioo Scientific Facilitates the Analysis of Melamine Contamination in Pharmaceutical Ingredients
In response to the Melamine Contamination Guidance recently announced by the U.S. Food and Drug Administration (FDA), Bioo Scientific is developing protocols to allow the MaxSignal® Melamine Enzymatic Assay Kit to be used to screen pharmaceutical ingredients for melamine contamination. Earlier this month the FDA announced that certain pharmaceutical ingredients used in the manufacture of drug products should be tested for melamine. Melamine is a dangerous, nitrogen rich organic compound that has been recently found in milk products and pet food. Consumption of melamine causes highly insoluble melamine cyanurate crystals to form in the kidney, which damage renal cells and can result in renal failure or death. While melamine contamination has not been found in pharmaceutical products, the FDA wants to implement controls to assure consumers that melamine contamination of the pharmaceutical supply chain will not occur.
Bioo Scientific’s MaxSignal Melamine Enzymatic Assay Kit allows pharmaceutical companies to quickly and inexpensively screen pharmaceutical ingredients for melamine contamination. The MaxSignal Melamine Enzymatic Assay Kit is a rapid aqueous extraction method that is able to detect down to 0.2 ppm of melamine. According to Dr. Joe Krebs, Director of Protein Chemistry and Engineering at Bioo Scientific, “The robust, specific ability of our unique enzyme reagent to detect melamine in a wide range of chemical matrices makes the Bioo Melamine Enzymatic Assay Kit the ideal choice for rapid, cost-effective detection of melamine adulteration in pharmaceutical components.” Bioo Scientific looks forward to working closely with the pharma industry to address this growing health concern. The MaxSignal® Melamine Enzymatic Assay Kit is a USDA funded project (2008-33610-18948).
Bioo Scientific’s MaxSignal Melamine Enzymatic Assay Kit allows pharmaceutical companies to quickly and inexpensively screen pharmaceutical ingredients for melamine contamination. The MaxSignal Melamine Enzymatic Assay Kit is a rapid aqueous extraction method that is able to detect down to 0.2 ppm of melamine. According to Dr. Joe Krebs, Director of Protein Chemistry and Engineering at Bioo Scientific, “The robust, specific ability of our unique enzyme reagent to detect melamine in a wide range of chemical matrices makes the Bioo Melamine Enzymatic Assay Kit the ideal choice for rapid, cost-effective detection of melamine adulteration in pharmaceutical components.” Bioo Scientific looks forward to working closely with the pharma industry to address this growing health concern. The MaxSignal® Melamine Enzymatic Assay Kit is a USDA funded project (2008-33610-18948).
Wednesday, July 29, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
Bioo Scientific, an Austin, TX based biotechnology company, announced today that it has been awarded a $500,000 Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation for the development of a targeted in vivo RNA Interference (RNAi) delivery technology. RNAi is an invaluable technique to characterize gene function and is being evaluated for the treatment of numerous human diseases. According to Lance Ford, Bioo Scientific’s VP of Research and Business Development, “While technologies are widely available for RNAi agent delivery into cells grown on plastic dishes in specially designed incubators, to fully understand gene functions and cellular pathways, in vitro results must be validated in animals. Currently, there are no commercial technologies for the targeted, in vivo delivery of RNAi agents and Bioo Scientific intends to fill this gap”. This grant will enable Bioo Scientific to develop kits and reagents based on the patent-pending Targeted Transport Technology (T3).
T3 involves conjugating an RNAi agent carrier to a monoclonal antibody (mAb) to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the mAb. The RNAi agent is then released to reduce the expression of its intended target. T3 will propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
T3 involves conjugating an RNAi agent carrier to a monoclonal antibody (mAb) to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the mAb. The RNAi agent is then released to reduce the expression of its intended target. T3 will propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
Wednesday, May 13, 2009
Top 10 Trends in Life Science Marketing Webinar
Please join us for this free, 45-minute webinar and learn about the top 10 trends that are changing the face of life science marketing. Constrained budgets, technological advancements, and changes in customers’ expectations are a few of the drivers of these trends. This session will provide a summary of these key trends and discuss how to use them to connect with life scientists.
What you will learn:
The webinar will be held on May 28th at 12:00 Eastern Time
Register now
What you will learn:
- How to effectively deploy webinars for increased brand awareness and pipeline fortification
- Three simple suggestions for gaining immediate benefit from social marketing
- The rise and importance of virtual trade shows
- Online advertising options that generate optimal results
- Leveraging mobile technology for life science marketing
The webinar will be held on May 28th at 12:00 Eastern Time
Register now
Subscribe to:
Posts (Atom)
Posts
